Foghorn Therapeutics Inc. (FHTX) Tops Q3 EPS by 12c

Foghorn Therapeutics Inc. (NASDAQ: FHTX) reported Q3 EPS of ($0.31), $0.12 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $7.81 million versus the consensus estimate of $6.34 million.

For earnings history and earnings-related data on Foghorn Therapeutics Inc. (FHTX) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Appeals court allows Trump administration to expand fast-track deportation process
• Daiwa Securities Downgrades JD.com, Inc (JD) to Hold